Annika Kim
Annika Kim Constantino is a digital reporter at CNBC, where she covers the biotech and pharmaceutical industry. She joined CNBC in June 2021 as a digital news intern and served as a news associate before joining the health team. Annika graduated with a bachelor's degree from the University of California, Berkeley in 2022.
Biography:
https://www.cnbc.com/annika-kim-constantino/
86%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
98%
Examples:
- Annika Kim Constantino covers the biotech and pharmaceutical industry for CNBC Digital.
Conflicts of Interest
99%
Examples:
No current examples available.
Contradictions
88%
Examples:
- CEO Tim Wentworth cited a
Deceptions
60%
Examples:
- Around 18% of adults ages 50 to 64 said they have taken a GLP-1 before.
- The latest case was announced Wednesday in a dairy farm worker in Michigan.
Recent Articles
New Weight Loss Drug Liraglutide Shows Promise in Slowing Cognitive Decline and Reducing Brain Shrinkage in Alzheimer's Patients: Potential Neuroprotective Effects
Broke On: Tuesday, 30 July 2024Liraglutide, a weight loss drug similar to Ozempic, shows potential in slowing cognitive decline and reducing brain shrinkage in patients with mild Alzheimer's disease according to recent research. The drug may have neuroprotective effects beyond managing diabetes and weight loss. Phase 3 clinical trials are expected to begin soon with potential FDA approval happening as early as next year. 
FDA Approves Eli Lilly's Donanemab: A New Hope for Early Alzheimer's Disease Patients
Broke On: Tuesday, 02 July 2024The FDA approves Eli Lilly's donanemab, the second drug for treating early Alzheimer's symptoms. This first-of-its-kind treatment targets amyloid protein deposits in the brain and slows down disease progression, allowing patients to live more independently. Despite reported side effects, benefits outweigh risks with a 39% reduced risk of clinical stage progression. Donanemab costs $12,522 for six months or about $32,000 per year. 
Walgreens Cuts Full-Year Profit Outlook, Announces Store Closures Amid Challenging Consumer Environment
Broke On: Thursday, 27 June 2024Walgreens lowers full-year profit outlook due to weak consumer spending, announces store closures and cost-cutting measures in response. CEO Tim Wentworth cites stunned consumers and pressure from competitors as challenges. The pharmacy chain has faced financial struggles for years, including declining prescription drug revenues and stock drops. 
Novo Nordisk's $4.1 Billion Investment: Building a New Facility in North Carolina, Creating 1,000 Jobs
Broke On: Monday, 24 June 2024Danish pharmaceutical company Novo Nordisk is investing $4.1 billion to build a new manufacturing facility in Clayton, North Carolina, creating 1,000 jobs and marking the largest single life science investment in NC history. The facility will expand production of weight-loss drug Wegovy and diabetes treatment Ozempic due to high demand. 
New Drug Tirzepatide Shows Promise in Improving Obstructive Sleep Apnea Symptoms: Study Findings and FDA Request
Broke On: Friday, 21 June 2024New studies suggest that tirzepatide, a compound in Zepbound, alleviates symptoms of obstructive sleep apnea for individuals with obesity. These findings were published in the New England Journal of Medicine and presented at an ADA conference. Eli Lilly, the manufacturer and funder of these trials, has requested FDA approval to expand Zepbound's use for this condition, potentially making it the first drug specifically designed to treat obstructive sleep apnea. 
New Merck Vaccine, Capvaxive, Secures FDA Approval for Adult Protection Against Pneumococcal Diseases: 85% Effectiveness and Fewer Side Effects Than Pfizer's Prevnar
Broke On: Monday, 17 June 2024Merck's new pneumococcal vaccine, Capvaxive, receives FDA approval for protecting adults from bacterial infections leading to pneumonia and meningitis. With coverage against 21 strains of bacteria and ability to prevent 85% of invasive diseases in older adults, it aims to surpass Pfizer's Prevnar. Capvaxive is well-tolerated with common side effects including pain, fatigue, headache, and muscle aches. No reports of Guillain-Barré syndrome have been recorded. 
Moderna's Promising Combination Vaccine for Covid-19 and Flu: Higher Immune Responses and Convenient Protection
Broke On: Monday, 10 June 2024Moderna's combination vaccine for Covid-19 and flu demonstrates higher immune responses than licensed comparator vaccines in adults aged 50 and older during phase-three trials. The vaccine targets H1N1, H3N2, and B/Victoria strains. CEO Stéphane Bancel believes that combination vaccines can reduce the burden on health systems and provide stronger protection from seasonal illnesses. 
CDC Warns of Increased Bird Flu Risk to Human Health: Two Confirmed Cases and Over 350 Monitored in US
Broke On: Sunday, 26 May 2024Two human cases of bird flu, caused by the highly pathogenic avian influenza A(H5N1) virus, have been confirmed in the US in farm workers. The CDC recommends avoiding close contact with sick or dead animals and has interim recommendations for prevention and public health investigations. Over 350 people have been monitored due to exposure to infected animals. Sixteen dairy cow herds in nine states have confirmed cases, and the USDA is providing financial support for biosecurity plans, veterinary costs, and sample shipping for testing. 
One in Eight Americans Use GLP-1 Drugs for Chronic Conditions or Weight Loss: Affordability and Access Remain Challenges
Broke On: Wednesday, 15 May 2024One in eight adults in the US have used GLP-1 drugs like Ozempic or Mounjaro, primarily for managing chronic conditions or weight loss. Despite their popularity, affordability is a major concern, with half of users finding it difficult to pay. Older adults and those without Medicare coverage are particularly affected by shortages and high costs. Six in ten adults advocate for Medicare coverage for weight loss medications, but current policy prohibits it. :max_bytes(150000):strip_icc()/GettyImages-1239401338-13e17db8844241f1a997d6ebc04cc337.jpg)
Novavax and Sanofi's $1.2 Billion Deal: Developing a COVID-19 and Flu Vaccine Combination
Broke On: Friday, 10 May 2024Novavax and Sanofi announce a $1.2 billion deal to co-develop COVID-19 and flu vaccines, with an upfront payment of $500 million from Sanofi to Novavax and potential payments of up to $700 million based on milestones.